ssif safety update
TRANSCRIPT
![Page 1: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/1.jpg)
![Page 2: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/2.jpg)
L09: Safety Issues
Gavin Giovannoni
Blizard Institute of Cell and Molecular Science
Barts and The London School of Medicine and Dentistry
![Page 3: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/3.jpg)
Safety = Benefits - Risks
![Page 4: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/4.jpg)
Safety issues
• Misdiagnosis • Interferon-beta / glatiramer acetate • Fingolimod • Mitoxantrone • Natalizumab • Emerging therapies
– Alemtuzumab – BG12 – Teriflunomide – Laquinimod
![Page 5: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/5.jpg)
Misdiagnosis
![Page 6: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/6.jpg)
Lennon et al. Lancet 2004;364:2106-12.
NMO
![Page 7: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/7.jpg)
![Page 8: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/8.jpg)
![Page 9: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/9.jpg)
What constitutes a useful diagnostic test or set of criteria?
TARGET DISORDER
PRESENT ABSENT
DIAGNOSTIC
TEST RESULT
+ a b a + b
- c d c + d
a + c b + d a + b + c + d
From these we determine the sensitivity and specificity as follows:
SENSITIVITY = a/(a+c) > 80%
SPECIFICITY = d/(b+d) > 80%
Neurobiol Aging 1998; 19:109-116.
![Page 10: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/10.jpg)
A clinico-pathoanatomical study of multiple sclerosis diagnosis
SENSITIVITY = True+ve /(True+ve + False-ve)
Eye Department, Hvidovre Hospital, Denmark.
• Neuropathological examination of 518 consecutive patients with clinically definite MS revealed a correct diagnosis in 485 cases (94%).
• Clinical diagnosis had been established by a neurologist in all cases.
• Erroneous diagnosis included a variety of other neurological disorders.
• Also investigated was a randomly selected series of 33 patients with a clinical diagnosis of probable MS:
– post mortem confirmation of MS was obtained in circa 66%.
– The remainder the error pattern was similar to the above.
Engell T. Acta Neurol Scand. 1988 Jul;78(1):39-44.
![Page 11: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/11.jpg)
Kleinschmidt-DeMasters,et al. N Engl J Med. 2005 Jul 28;353(4):369-74.
PML complicating treatment with natalizumab and IFNb-1a for MS
![Page 12: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/12.jpg)
Established therapies
Interferon beta Glatiramer Acetate
Fingolimod Mitoxantrone Natalizumab
![Page 13: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/13.jpg)
Interferon beta
![Page 14: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/14.jpg)
What is the diagnosis?
![Page 15: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/15.jpg)
![Page 16: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/16.jpg)
Take special care with Interferon-beta-1b: If you might have a disorder of the immune system in which abnormal proteins are found in the blood (monoclonal gammopathy), you must check this with your doctor before you use interferon beta-1b. Patients who have the rare condition known as monoclonal gammopathy may develop problems with their small blood vessels (capillaries) leading to shock (collapse) which can be fatal, when they use medicines like interferon-beta-1b. See also 4. Possible side effects.
![Page 17: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/17.jpg)
![Page 18: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/18.jpg)
![Page 19: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/19.jpg)
Glatiramer Acetate
![Page 21: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/21.jpg)
Fingolimod
![Page 22: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/22.jpg)
![Page 23: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/23.jpg)
![Page 24: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/24.jpg)
![Page 25: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/25.jpg)
?
![Page 26: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/26.jpg)
![Page 27: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/27.jpg)
![Page 28: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/28.jpg)
![Page 29: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/29.jpg)
Could sudden death be due to MS?
![Page 30: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/30.jpg)
Relapsing and Remitting Multiple Sclerosis: Pathology of the Newly Forming Lesion
Barnett & Prinea. Ann Neurol 2004;55:458–468.
![Page 31: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/31.jpg)
Sudden death in multiple sclerosis (SUDMUS)
![Page 32: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/32.jpg)
www.adverseevents.com
![Page 33: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/33.jpg)
www.adverseevents.com
![Page 34: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/34.jpg)
We need to define a new entity:
SUDMUS Sudden death in multiple sclerosis
![Page 35: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/35.jpg)
Mitoxantrone
![Page 36: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/36.jpg)
Mitoxantrone-related leukaemia
Mistry et al. Engl J Med. 2005 Apr 14;352(15):1529-38.
![Page 37: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/37.jpg)
Treatment-related leukaemia mitoxantrone
mitoxantrone
Mitoxantrone
![Page 38: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/38.jpg)
1 in 244
![Page 39: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/39.jpg)
1 in 108
![Page 40: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/40.jpg)
![Page 41: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/41.jpg)
/MITOXANTRONE
![Page 42: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/42.jpg)
Natalizumab
![Page 43: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/43.jpg)
Natalizumab
Progressive multifocal leukoencephalopathy (PML)
Kleinschmidt-DeMasters,et al. N Engl J Med. 2005 Jul 28;353(4):369-74.
359 cases -30th April 2013 83 (23%) died 276 (77%) alive
Mild disability – 10% Moderate disability – 50% Severe disability – 40%
5% NAbs – infusion reactions
![Page 44: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/44.jpg)
Prior disease modifying treatments for MS
~50 % of PML cases have had prior chemotherapy
exposure both in Europe and US
28 cases – Clifford et al. Lancet Neurol. 2010 Apr;9(4):438-46. 42 cases – Clifford et al; AAN 2010.
Slide courtesy of David Clifford
![Page 45: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/45.jpg)
Natalizumab PML risk stratification tool
Anti-JC virus antibody status
Negative Positive
Prior immunosuppressant use
Natalizumab treatment
>2 Years
Natalizumab treatment
>2 Years
No Yes
No Yes No Yes
Lowest Highest Relative PML Risk
< 1 in 10,000 1 in 94 1 in 256 1 in 668 1 in 1887
Mitoxantrone
Azathioprine
Methotrexate
Cyclophosphamide
Mycophenolate
Cladribine
Rituximab
Etc.
![Page 46: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/46.jpg)
![Page 47: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/47.jpg)
![Page 48: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/48.jpg)
![Page 49: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/49.jpg)
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
Khatri et al. Neurology 2009;72:402–409
![Page 50: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/50.jpg)
Emerging therapies
Alemtuzumab BG12
Laquinomod Teriflunomide
![Page 51: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/51.jpg)
Alemtuzumab
![Page 52: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/52.jpg)
N Engl J Med 2008;359:1786-801. Coles et al. Mult Scler. 1998;4:232-8.
![Page 53: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/53.jpg)
Humoral autoimmunity syndromes as a complication of Alemtuzumab therapy: associated with immune
reconstitution post lymphocyte depletion
• Alemtuzumab (anti-CD52)
• Grave’s disease ~30%
• Immune-mediated thrombocytopaenia (ITP) ~2-3%
• Goodpasture’s syndrome – 3 cases
• Immune-mediated neutropaenia – 1 case
• Immune-mediated haemolytic anaemia
• Well described in other clinical settings
• AIDS & HAART
• Chemotherapy
• Bone marrow transplantation
• Anti-TPO Abs and raised baseline IL21 predictive of post-alemtuzumab autoimmunity
• Possibly related to imbalance between regulatory, memory and naïve T cell reconstitution
![Page 54: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/54.jpg)
Tranexamic Acid
![Page 55: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/55.jpg)
Predicting autoimmunity following treatment of MS with alemtuzumab
• 30% of alemtuzumab-treated pts develop autoimmune side-effects (primarily thyroid disease and idiopathic thrombocytopenia)
• Aim: To define predictive factors for autoimmune side-effects
• Sera of 141 pts screened at baseline for 8 different cytokines/chemokines
A combined IL-21/IL-7 test on pre-treatment serum may be useful to identify patients at low risk of developing autoimmunity following treatment with alemtuzumab
Jones JL, et al. ECTRIMS 2011, Amsterdam. P1009
Sensitivity NPV Specificity PPV
IL-21 alone 81 84 70 66
IL-7 alone 76 76 54 54
CCL21 alone 63 65 49 47
IL-21 or IL-7 98 97 41 55
IL-21 OR IL-7 OR CCL21
98 91 12 45
Given that pts may elect to receive treatment based
on results of this test – most weight given to
minimizing false negative results. Combining IL-21
and IL-7 into a single test offers improved test
accuracy over IL-21 alone. CCL21 did not improve
test accuracy
0
10
20
30
40
IL-7
Autoimmunity No autoimmunity
0
500
1000
1500
IL-2
1
1.0
Se
nsit
ivit
y
0.8
0.6
0.4
0.2
0.0 0.0 0.2 0.4 0.6 0.8 1.0
1.0
Se
nsit
ivit
y
0.8
0.6
0.4
0.2
0.0 0.0 0.2 0.4 0.6 0.8 1.0
1-Specificity
IL-21 and IL-7 levels in sera
of pts who did or did not
develop autoimmunity
Receiver operating
characteristic (ROC) curves
![Page 56: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/56.jpg)
BG12
![Page 57: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/57.jpg)
![Page 58: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/58.jpg)
Laquinimod
![Page 59: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/59.jpg)
![Page 60: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/60.jpg)
Teriflunomide
![Page 61: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/61.jpg)
Teriflunomide - safety
O’Connor et al. N Engl J Med 2011;365:1293-303.
![Page 62: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/62.jpg)
Other issues
![Page 63: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/63.jpg)
Other issues
• Pregnancy
• Contraception
• Travel
– Vaccinations
– Anti-malarials
• Drug interactions
• Pharmacogenomics
![Page 64: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/64.jpg)
Conclusions
![Page 65: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/65.jpg)
Safety = Benefits - Risks
![Page 66: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/66.jpg)
• High unemployment rates; 50% unemployed within 10 years of diagnosis.
• High divorce rates; at least double the average
• MS is one of the most common causes of neurological disability in young adults2
• Natural history studies indicate that it takes a median time of 8, 20, and 30 years to reach the irreversible disability levels of EDSS 4, 6, and 7, respectively3
• Life expectancy is reduced by 5–10 years4
Uti
lity
EDSS Status
EDSS and utilitya show a significant inverse relationship
1,b
aUtility measures are derived from EQ-5D using the EuroQoL instrument. bError bars depict 95% confidence intervals. Half points on EDSS are not shown on graph axis, except at EDSS 6.5. EDSS, expanded disability status scale 1 Adapted from Orme M et al. Value In Health 2007;10:54–60; 2 WHO and MSIF http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1 &codcol=15&codcch=747 Accessed October 6, 2010; 3 Confavreaux C and Compston A, Mcalpine’s multiple sclerosis, 4th edn 2005; 4 Compston A et al. Lancet 2008; 372: 1502–17
MS is a debilitating disease
66
![Page 67: SSIF safety update](https://reader033.vdocuments.us/reader033/viewer/2022060112/556b8924d8b42a6c7c8b50e0/html5/thumbnails/67.jpg)
Conclusions
• MS is serious debilitating disease
• Risk: benefits
– Tolerability vs. serious AEs
– Defined and undefined risks
• Risks
– Active surveillance
– Manage risks
• LFTs and blood monitoring
• JCV serology & PLEX for PML
• VZV vaccination pre-fingolimod & SOPs for starting and
monitoring treatment
• Platelet, TFTs and urine monitoring for alemtuzumab
• Individualise treatments